NEW YORK (GenomeWeb) – Opko Health is hoping for a positive coverage decision from Medicare contractor Novitas as it continues to commercialize its 4Kscore test for prostate cancer.
The company noted during its Q4 2016 earnings call this month that it had expected Novitas to review the test during its February review cycle for draft local coverage determinations, but that the contractor had not yet announced LCDs for the 4Kscore or any other diagnostics in that cycle.
Get the full story with
GenomeWeb Premium Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.